Presented at: San Antonio Breast Cancer Symposium. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Early survival analysis of the randomized Phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). 5 Von Minckwitz G, Loibl S, Schneeweiss A.A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. 3 Rakovitch E, Nofech-Mozes S, Hanna W et al.RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. 2 McCormick B, Winter K, Hudis C et al.Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. 1 Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M.

Medical conferences 2016 florida